22nd Century Group, Inc. operates as a plant biotechnology company. Products RED SUN and MAGIC Cigarettes: The company’s subsidiary, Goodrich Tobacco Company, LLC (Goodrich Tobacco), introduced in a limited capacity two super-premium priced cigarette brands, RED SUN and MAGIC, into the U.S. market in 2011. Both of the RED SUN and MAGIC brands are available in regular and menthol, and all brand styles are king size and packaged in hinge-lid hard packs. SPECTRUM Government Research Cigarettes: In 2014, Goodrich Tobacco entered into a teaming agreement with RTI International (RTI) to work together to respond to a new request from National Institute on Drug Abuse (NIDA) for the potential purchase by NIDA from RTI of additional SPECTRUM research cigarettes to be produced and sold by Goodrich Tobacco to RTI. BRAND A and BRAND B: The tobacco in BRAND A contains approximately 95% less nicotine than tobacco in ‘light’ cigarette brands. Using a proprietary high nicotine tobacco blend in conjunction with specialty cigarette components, BRAND B allows the smoker to achieve a satisfactory amount of nicotine per cigarette while inhaling less ‘tar’ and carbon monoxide. X-22 Smoking Cessation Aid: X-22 is a tobacco-based botanical medical product for use as an aid to smoking cessation. The X-22 therapy protocol utilized in its sponsored Phase IIb clinical trial calls for the patient to smoke its very low nicotine (VLN) cigarettes over a six-week treatment period to facilitate the goal of the patient quitting smoking by the end of the treatment period. The company’s Investigational New Drug Application for X-22, a kit of VLN cigarettes, was cleared by the U.S. Food and Drug Administration (FDA) in 2011 and has been updated annually. Research and Development During the year ended December 31, 2014, the company incurred total research and development expenses of approximately $1,249,007. Intellectual Property The company owns or exclusively controls 128 issued patents plus an additional 52 pending patent applications. Competition In the market for FDA-approved smoking cessation aids, the company’s principal competitors include Pfizer Inc.; GlaxoSmithKline plc; Novartis International AG; and Perrigo Company plc. The company’s domestic competitors include Philip Morris USA; Reynolds American Inc.; Lorillard Inc.; Commonwealth Brands, Inc.; Liggett Group LLC; and Vector Tobacco Inc. Its international competitors include Philip Morris International, Inc.; Japan Tobacco Inc.; Imperial Tobacco Group plc; and regional and local tobacco companies. Significant Events In October 2014, 22nd Century Group has entered into a new cannabis research collaboration with strategic partner Anandia Laboratories. As a part of this research collaboration, Anandia would develop and grow cannabis strains that express highly desirable characteristics and would lead to commercialization opportunities. History 22nd Century Group, Inc. was founded in 1998.
22nd century group inc
(XXII:Consolidated issues listed on NYSE MKT LLC)
9530 Main Street
Clarence, NY 14031
|GlaxoSmithKline PLC||1,366 GBp||-6.00|
|Imperial Tobacco Group PLC||3,611 GBp||+5.00|
|Japan Tobacco Inc||¥4,495 JPY||-16.00|
|Perrigo Co PLC||$150.49 USD||-0.14|
|Reynolds American Inc||$46.84 USD||+0.27|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact 22ND CENTURY GROUP INC, please visit www.xxiicentury.com. Company data is provided by Capital IQ. Please use this form to report any data issues.